The firm has used its proximity ligation method to interpret metagenomic sequence data from a human fecal sample, unraveling new and known genomes in the mix.
The firms will use MGI's sequencing technology and Curetis' sample prep platform and antibiotic resistance database to develop IVDs, initially for China.
Ares plans to use the GEAR database to discover new markers of antibiotic resistance and will eventually develop it as an interpretation service.
Among other plans, CosmosID is using the funds to prep its platform for clinical use including running validation studies with partner hospitals.
Researchers generated a near complete genome sequence for a 5,300 year old Helicobacter pylori strain found in the gut of Ötzi, the Tyrolean Iceman.
The researchers demonstrated that the panel could identify pathogens in mock clinical samples even at very low levels, while unbiased sequencing could not.
The Toronto-based firm will use the funds to finance ongoing molecular diagnostics product development and expansion.
The Virginia-based firm will use the funds to build out its next-generation sequencing data analytics for pathogen identification and surveillance.
The funding comes as part of the agency's Advanced Molecular Detection initiative, which is using the technologies to help address infectious disease outbreaks.
The initiative aims to integrate clinical, genomic, environmental, and other data from patients to help determine disease mechanisms and develop precise therapies.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.